Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...
Here's Why. Ethereum remains a focal point for institutional on-chain activity even as price momentum stalls. In 2026, Ether has retreated about 36% for the year, slipping back from the $3,000 milesto ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果